A5018765384- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Monoclonal and Polyclonal Antibodies Research
- Chronic Lymphocytic Leukemia Research
- Immune Cell Function and Interaction
- Glycosylation and Glycoproteins Research
- Immune Response and Inflammation
- Cancer Genomics and Diagnostics
- Parvovirus B19 Infection Studies
- Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
- Gestational Trophoblastic Disease Studies
- Advanced Biosensing Techniques and Applications
- Cancer Risks and Factors
- COVID-19 and healthcare impacts
- Vascular Tumors and Angiosarcomas
- Maternal and fetal healthcare
- Biomedical Ethics and Regulation
- Acute Lymphoblastic Leukemia research
- Pregnancy and preeclampsia studies
- Breast Lesions and Carcinomas
- Cutaneous Melanoma Detection and Management
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Testicular diseases and treatments
University of Rochester Medical Center
2016-2024
University of Rochester
2017-2024
Strong Memorial Hospital
2019
We assessed the interobserver and interantibody reproducibility of HER2 immunohistochemical scoring in an enriched HER2-low-expressing breast cancer cohort.A total 114 specimens were stained by HercepTest (Agilent Dako) PATHWAY anti-HER2 (4B5) (Ventana) antibody assays scored 6 pathologists independently using current guidelines. Level agreement was evaluated Cohen κ analysis.Although rate for both antibodies achieved substantial agreement, average significantly higher than that 4B5 clone...
Primary esophageal malignant melanoma (MM) is rare and extremely aggressive. For pathologists, it can be challenging to diagnose differentiate from other poorly differentiated neoplasms in the esophagus. Complicating this fact, MM have divergent differentiation express nonmelanocytic immunohistochemical markers including epithelial (cytokeratins) rarely neuroendocrine markers. Lack of awareness fact by a pathologist lead an erroneous diagnosis delay treatment for already aggressive disease....
Vascular lesions are uncommonly encountered in the breast and they represent a spectrum of benign, atypical malignant entities. The mammary angiosarcomas can be primary arising de novo, or most frequently secondary to prior radiation therapy for carcinoma. There is significant overlap pathologic features between vascular their non-vascular mimics, as well benign counterparts, resulting diagnostic dilemma, especially core biopsy setting. In this article, we review clinico-radiological...
As breast cancer treatment options continue to evolve, biomarker and multigene assay testing are now considered a standard part of the clinical evaluation estrogen receptor (ER) positive, human epidermal growth factor 2 (HER-2) negative carcinomas. These methodologies used measure recurrence risk tailor both hormonal chemotherapy options. There several international guidelines which address use for ER HER-2 carcinoma. Each guideline has specific recommendations as prognostic predictive value...
Anemia commonly occurs in systemic lupus erythematosus, a disease characterized by innate immune activation nucleic acids. Overactivation of cytoplasmic sensors self-DNA or RNA can cause erythroid cell death, while sparing other hematopoietic lineages. Whereas chronic inflammation is involved this mechanism, less known about the impact erythematosus on BM erythropoietic niche. We discovered that expression endosomal ssRNA sensor human TLR8 induces fatal anemia Sle1.Yaa mice. observed was...
Introduction Chorionic cysts of the chorion laeve, fetal chorionic plate, septum, and free membranes have been associated with placental hypoxia, but they no clear clinical significance. Although immunohistochemistry has identified fibronectin collagen IV in cyst fluid, contents yet to be fully characterized. Methods Placental (N = 10) were sampled by fluid extraction hemotoxylin eosin-stained sections. Amniotic samples 8) obtained from pregnant women who had cytogenetic evaluation. The...
<h3></h3> Anemia commonly occurs in systemic lupus erythematosus (SLE), a disease characterized by innate immune activation nucleic acids. Overactivation of cytoplasmic sensors self-DNA or RNA can cause erythroid cell death while sparing other hematopoietic lineages. However, little is currently known about the impact acid sensing receptors on bone marrow (BM) erythropoietic niche. The ssRNA endosomal TLR7 and human TLR8 both recognize ssRNA. overexpression causes syndrome that includes...
Introduction: Multigene genomic profiling has become the standard of care in clinical risk-assessment and risk-stratification ER+, HER2− breast cancer (BC) patients, with Oncotype DX® (ODX) emerging as profile test most support from international community. The current state health economy demands that cost-efficiency access to testing must be considered when evaluating utility multigene tests such ODX. Several studies have suggested certain lower risk patients can identified more...
Hemophagocytic lymphohistiocytosis (HLH) is a rare and life-threatening syndrome of immune system dysregulation characterized by the phagocytosis various cells histiocytes in bone marrow. HLH can present one two ways: primary HLH, which caused mutations genes essential to T NK-cell function, secondary typically Epstein–Barr virus (EBV) infection or malignancy. Because rapid progression high mortality this disease, prompt diagnosis good outcomes. Here, we report 2-month clinical course...
Abstract Objectives B-cell clonality assays of the immunoglobulin heavy chain (IGH) and light (IGK) genes have been used widely in workup neoplasms. PCR is current gold standard test for clonality. Recently, NGS has suggested to both improve sensitivity identify specific V-(D-)J sequence required track clones. Here we report our experience with using complementing procedures. Methods Our validated performed by amplifying patients’ DNA IGH-FR1 assay panel. Pooled amplicons get sequenced. The...
Abstract Objectives: Recently-published phase I clinical trials have demonstrated promising efficacy of novel HER2-targeted therapy in advanced breast cancers with a HER2 immunohistochemistry (IHC) score 1+, or 2+ non-amplified in-situ hybridization (ISH). This has raised the possibility for changing categories interpretation into: 1) HER2-negative (HER2 IHC 0+), 2) HER2-low (IHC ISH), and 3) HER2-positive 3+ amplified ISH). Earlier studies on low HER2-expressing focused differences between...
Abstract Background: MammaPrint (MP) is an FDA approved early breast cancer prognostic genomic assay that examines the expression levels of 70 genes and classifies clinically high-risk patients with early-stage into low or high risk distant metastasis. Current ASCO guidelines do not support using MP testing in low-risk patients. Historically, assessing a patient’s clinical for recurrence has relied on subjective evaluation histologic factors, immunohistochemical features, characteristics....
Abstract Introduction: The COVID-19 pandemic has caused an extraordinary challenge for global health. New guidelines were implemented, including postponing non-essential surgical procedures to conserve resources. In response, the COVID19 Pandemic Breast Cancer Consortium expert opinion suggested use of core biopsies genomic testing help triage patients vs. systemic treatment. To better understand how expedited results could impact peri-operative care, we performed a pre-operative quality...
Abstract INTRODUCTION: Oncotype DX® (ODX) is a multigene assay estimating risk of distant recurrence and chemotherapy benefit in estrogen receptor (ER) positive breast cancer patients. Cost ($4,620.00) impedes its adoption poorer countries, the cost unnecessary certain TAILORx results suggest that adjuvant endocrine therapy chemoendocrine had similar efficacy women with hormone-positive, HER2-negative, node-negative invasive carcinomas an ODX score &lt; 26. Bhargava et al. Turner have...
Abstract INTRODUCTION: The literature suggests that there is no difference in the Oncotype DX® (ODX) recurrence score between African American (AA) women and Caucasian (CA) women; however, an analysis of clinical outcomes participants enrolled TAILORx trial found AA had worse than CA women, despite similar ODX scores. suggested chemoendocrine therapy may not be necessary with hormone-positive, HER2-negative, node-negative invasive breast carcinomas &lt; 26. We examine Ki-67 (a marker...
Adult patients with B-cell acute lymphoblastic leukemia (ALL) have higher rates of antecedent and subsequent malignancies. However, synchronous identification ALL ovarian cancer is exceedingly rare. We report the unique case a 65-year-old woman low-grade serous carcinoma diagnosed after surgical intervention for small bowel obstruction. Treatment inotuzumab ozogamicin followed by adnexal mass resection postoperative letrozole was successful in achieving complete remission both her cancer.